Chronic Neuroleptic Therapy and Progressive Parkinsonism: A Case Report

1Department of Pharmacy Practice, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education and Research, Belagavi), Vidyanagar, Hubballi, Karnataka, INDIA

Corresponding author.

Correspondence: Dr. Sanatkumar Bharamu Nyamagoud Assistant Professor, Department of Pharmacy Practice, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education and Research, Belagavi), Vidyanagar, Hubballi, Karnataka, INDIA. Email: dr.sanathnyamagoud@gmail.com
Received December 12, 2023; Revised January 05, 2024; Accepted January 12, 2024.
Copyright 2024 Authors
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Citation

1.Rao A, Reddy S, Bharamu Nyamagoud S, Hiremath Viswanatha Swamy A. Chronic Neuroleptic Therapy and Progressive Parkinsonism: A Case Report. Journal of Young Pharmacists [Internet]. 2024 Feb 15;16(1):137–8. Available from: http://dx.doi.org/10.5530/jyp.2024.16.19
Copy to clipboard
Published in: Journal of Young Pharmacists, 2024; 16(1): 137-138. Published online: 07 July 2025DOI: 10.5530/jyp.2024.16.19

ABSTRACT

This case report presents the challenging clinical scenario of a middle-aged male patient with a decade-long history of psychiatric illness on chronic neuroleptic therapy. The patient’s symptoms initially manifested as tremors a year ago, subsequently progressing to resting tremors, head titubation, and impaired mobility. Typically, Drug-Induced Parkinsonism (DIP) occurs within three months of initiating neuroleptic treatment, this case presents a unique and prolonged timeline, raising questions about the underlying aetiology complexed with patients’ imaging studies revealing age related atrophy. The bilateral and symmetrical motor signs observed align with DIP characteristics, although studies report asymmetrical signs, introducing diagnostic complexities. This case emphasizes the need for further research on understanding the effect of chronic neuroleptic use, age-related structural alterations, and the potential unmasking of underlying Parkinsonism for improving diagnostic accuracy and tailoring effective management strategies for patients with similar challenging presentations.
Keywords: Prolonged neuroleptic exposure, Parkinsonian symptoms, Drug-Induced Parkinsonism, Anti-psychotic therapy, Extrapyramidal symptoms, Age-related cerebral atrophy